Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model

Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder for which effective treatment strategies are insufficient. Butyrate, a microbiota-derived short-chain fatty acid believed to strengthen the intestinal barrier function, might be a potential new treatment option. This study aimed...

Full description

Saved in:
Bibliographic Details
Main Authors: Mathias W. Scharf, Richard A. Forsgård, Samira B. R. Prado, John-Peter Ganda Mall, Dirk Repsilber, Robert J. Brummer, Tatiana M. Marques, Rebecca Wall
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Gut Microbes
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/19490976.2025.2545414
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849239392396247040
author Mathias W. Scharf
Richard A. Forsgård
Samira B. R. Prado
John-Peter Ganda Mall
Dirk Repsilber
Robert J. Brummer
Tatiana M. Marques
Rebecca Wall
author_facet Mathias W. Scharf
Richard A. Forsgård
Samira B. R. Prado
John-Peter Ganda Mall
Dirk Repsilber
Robert J. Brummer
Tatiana M. Marques
Rebecca Wall
author_sort Mathias W. Scharf
collection DOAJ
description Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder for which effective treatment strategies are insufficient. Butyrate, a microbiota-derived short-chain fatty acid believed to strengthen the intestinal barrier function, might be a potential new treatment option. This study aimed to investigate potential protective effects of acute in vivo butyrate exposure on intestinal barrier function in healthy subjects and patients with IBS. For this, we used an experimental colonoscopy-perfusion model for colon-specific butyrate delivery and adequate tissue sampling. Seventeen IBS and 17 healthy subjects underwent a colonoscopy procedure exposing a predefined colonic area to 100 mmol/L butyrate for 90 min in vivo. Mucosal biopsies collected pre- and post-butyrate exposure were stimulated in Ussing chambers with/without sodium deoxycholate (DC) to induce intestinal hyperpermeability. Intestinal permeability was measured by fluorescein isothiocyanate-dextran and horseradish peroxidase passage. DC-stimulation significantly increased para- and transcellular permeability in biopsies collected pre-butyrate exposure. DC-induced transcellular hyperpermeability was significantly alleviated in biopsies collected post-butyrate exposure compared to pre-exposure in patients with IBS (p = 0.034). In conclusion, we established a colonoscopy research model for colon-specific delivery and sampling and demonstrated acute protective effects of butyrate on transcellular intestinal permeability in patients with IBS. The results support butyrate’s potential role in novel treatment strategies in IBS. Clinicaltrials.gov number: NCT05249023
format Article
id doaj-art-9f9943441d7449be836fa8b4ae44a56b
institution Kabale University
issn 1949-0976
1949-0984
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Gut Microbes
spelling doaj-art-9f9943441d7449be836fa8b4ae44a56b2025-08-20T04:01:01ZengTaylor & Francis GroupGut Microbes1949-09761949-09842025-12-0117110.1080/19490976.2025.2545414Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research modelMathias W. Scharf0Richard A. Forsgård1Samira B. R. Prado2John-Peter Ganda Mall3Dirk Repsilber4Robert J. Brummer5Tatiana M. Marques6Rebecca Wall7Nutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, SwedenNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, SwedenNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, SwedenNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, SwedenNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, SwedenNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, SwedenNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, SwedenNutrition-Gut-Brain Interactions Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, SwedenIrritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder for which effective treatment strategies are insufficient. Butyrate, a microbiota-derived short-chain fatty acid believed to strengthen the intestinal barrier function, might be a potential new treatment option. This study aimed to investigate potential protective effects of acute in vivo butyrate exposure on intestinal barrier function in healthy subjects and patients with IBS. For this, we used an experimental colonoscopy-perfusion model for colon-specific butyrate delivery and adequate tissue sampling. Seventeen IBS and 17 healthy subjects underwent a colonoscopy procedure exposing a predefined colonic area to 100 mmol/L butyrate for 90 min in vivo. Mucosal biopsies collected pre- and post-butyrate exposure were stimulated in Ussing chambers with/without sodium deoxycholate (DC) to induce intestinal hyperpermeability. Intestinal permeability was measured by fluorescein isothiocyanate-dextran and horseradish peroxidase passage. DC-stimulation significantly increased para- and transcellular permeability in biopsies collected pre-butyrate exposure. DC-induced transcellular hyperpermeability was significantly alleviated in biopsies collected post-butyrate exposure compared to pre-exposure in patients with IBS (p = 0.034). In conclusion, we established a colonoscopy research model for colon-specific delivery and sampling and demonstrated acute protective effects of butyrate on transcellular intestinal permeability in patients with IBS. The results support butyrate’s potential role in novel treatment strategies in IBS. Clinicaltrials.gov number: NCT05249023https://www.tandfonline.com/doi/10.1080/19490976.2025.2545414IBSintestinal barrier functionin vivoUssing chamber
spellingShingle Mathias W. Scharf
Richard A. Forsgård
Samira B. R. Prado
John-Peter Ganda Mall
Dirk Repsilber
Robert J. Brummer
Tatiana M. Marques
Rebecca Wall
Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model
Gut Microbes
IBS
intestinal barrier function
in vivo
Ussing chamber
title Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model
title_full Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model
title_fullStr Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model
title_full_unstemmed Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model
title_short Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model
title_sort acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model
topic IBS
intestinal barrier function
in vivo
Ussing chamber
url https://www.tandfonline.com/doi/10.1080/19490976.2025.2545414
work_keys_str_mv AT mathiaswscharf acuteeffectsofbutyrateonintestinalpermeabilityinpatientswithirritablebowelsyndromeassessedbyanovelcolonoscopyresearchmodel
AT richardaforsgard acuteeffectsofbutyrateonintestinalpermeabilityinpatientswithirritablebowelsyndromeassessedbyanovelcolonoscopyresearchmodel
AT samirabrprado acuteeffectsofbutyrateonintestinalpermeabilityinpatientswithirritablebowelsyndromeassessedbyanovelcolonoscopyresearchmodel
AT johnpetergandamall acuteeffectsofbutyrateonintestinalpermeabilityinpatientswithirritablebowelsyndromeassessedbyanovelcolonoscopyresearchmodel
AT dirkrepsilber acuteeffectsofbutyrateonintestinalpermeabilityinpatientswithirritablebowelsyndromeassessedbyanovelcolonoscopyresearchmodel
AT robertjbrummer acuteeffectsofbutyrateonintestinalpermeabilityinpatientswithirritablebowelsyndromeassessedbyanovelcolonoscopyresearchmodel
AT tatianammarques acuteeffectsofbutyrateonintestinalpermeabilityinpatientswithirritablebowelsyndromeassessedbyanovelcolonoscopyresearchmodel
AT rebeccawall acuteeffectsofbutyrateonintestinalpermeabilityinpatientswithirritablebowelsyndromeassessedbyanovelcolonoscopyresearchmodel